UNSPSC 51112513: Melphalan

This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q41OR9510P, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)- but more generally known as melphalan, which bears US NIH Compound Identifier 4053. European Medicines Agency schedules Melphalan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08728MIG.

UNSPSC 51112513 Melphalan is a Commodity code covering the pharmaceutical product melphalan, a chemotherapy agent. State and local governments procure melphalan primarily through pharmacy benefit programs, state health and human services agencies, and institutional healthcare systems serving Medicaid populations, correctional facilities, and state employees. The code captures both the drug itself and the contracting mechanisms through which it flows to end-use patients — including traditional pharmacy benefit manager (PBM) channels, direct-to-manufacturer arrangements, and group purchasing organization (GPO) relationships. Recent activity shows states exploring direct contracting models with pharmaceutical manufacturers to bypass traditional PBM and wholesaler intermediaries in pursuit of cost containment and improved prescription fulfillment efficiency, particularly for specialty pharmaceuticals within state health programs.

Texas Health and Human Services Commission posted a Request for Information (RFI) in early April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program designed to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The RFI, posted April 3, 2026 with response due the same day, solicited information from vendors and stakeholders about direct contracting capacity outside traditional PBM, GPO, and wholesaler arrangements, with particular focus on experience serving self-insured employers and health plans, flexibility to negotiate on net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The RFI represents an exploratory phase preceding formal procurement; no award values, budget ranges, set-asides, or formal evaluation criteria were specified. Recent opportunities in this code remain limited to this single documented state-level activity, indicating the code sees modest recent engagement from state and local procurement offices.